Denali Therapeutics Inc. $DNLI Stock Sold by Candriam S.C.A.

Key Points

• Candriam S.C.A. reduced its Denali Therapeutics stake by 10.1% in the third quarter, selling 120,350 shares. It still held 1,069,536 shares, worth about $22.2 million.
• Denali reported quarterly EPS of $0.37, beating analyst expectations of a $0.27 loss, while revenue of $17.78 million topped the $12.67 million consensus.
• Analysts maintain a “Moderate Buy” consensus rating and an average price target of $36.15; one company insider also sold 2,857 shares.

Candriam S.C.A. trimmed its stake in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 10.1% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,069,536 shares of the company's stock after selling 120,350 shares during the quarter. Candriam S.C.A. owned about 0.67% of Denali Therapeutics worth $22,188,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of DNLI. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of Denali Therapeutics during the 2nd quarter worth $26,000. Global Retirement Partners LLC acquired a new stake in Denali Therapeutics during the second quarter worth about $28,000. Nykredit A S acquired a new stake in Denali Therapeutics during the second quarter worth about $38,000. Allworth Financial LP purchased a new position in shares of Denali Therapeutics in the 2nd quarter worth about $47,000. Finally, Manchester Capital Management LLC raised its holdings in shares of Denali Therapeutics by 5,505.6% in the 3rd quarter. Manchester Capital Management LLC now owns 2,018 shares of the company's stock worth $42,000 after purchasing an additional 1,982 shares during the period. Institutional investors and hedge funds own 92.92% of the company's stock.

Insider Buying and Selling at Denali Therapeutics

In other news, insider Alexander O. Schuth sold 2,857 shares of the company's stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $25.07, for a total value of $71,624.99. Following the completion of the transaction, the insider directly owned 281,763 shares in the company, valued at approximately $7,063,798.41. This represents a 1.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 9.70% of the company's stock.

Denali Therapeutics Stock Performance

Denali Therapeutics stock opened at $20.07 on Monday. The stock's 50 day moving average price is $20.16 and its 200 day moving average price is $21.27. The firm has a market capitalization of $3.22 billion, a PE ratio of -11.60 and a beta of 1.08. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.94 and a current ratio of 6.21. Denali Therapeutics Inc. has a one year low of $13.75 and a one year high of $27.30.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last posted its quarterly earnings data on Tuesday, November 3rd. The company reported $0.37 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.27) by $0.64. The firm had revenue of $17.78 million for the quarter, compared to analysts' expectations of $12.67 million. During the same quarter in the prior year, the business earned ($0.74) EPS. As a group, sell-side analysts expect that Denali Therapeutics Inc. will post -1.94 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on DNLI shares. Robert W. Baird set a $34.00 price objective on Denali Therapeutics in a research note on Friday, August 7th. Wedbush lifted their price target on shares of Denali Therapeutics from $23.00 to $24.00 and gave the company an "outperform" rating in a research report on Wednesday, November 4th. Morgan Stanley boosted their price objective on shares of Denali Therapeutics from $40.00 to $42.00 and gave the stock an "overweight" rating in a research note on Wednesday, November 4th. HC Wainwright assumed coverage on shares of Denali Therapeutics in a research report on Wednesday, November 4th. They issued a "strong-buy" rating for the company. Finally, BTIG Research reissued a "buy" rating and issued a $39.00 price objective on shares of Denali Therapeutics in a research report on Wednesday, November 4th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $36.15.

Key Denali Therapeutics News

Here are the key news stories impacting Denali Therapeutics this week:

• Positive Sentiment: Denali’s third-quarter results beat expectations: EPS was $0.37 versus the consensus estimate of a $0.27 loss, and revenue was $17.78 million versus a $12.67 million estimate. Denali Therapeutics earnings beat and valuation article
• Positive Sentiment: Commercial momentum and potential catalysts may be lifting sentiment: a report cited nearly fivefold growth in Avlayah sales, broader reimbursement coverage, and multiple upcoming pipeline catalysts. Shares were reported up 7.8% after the earnings release. Zacks report on Denali post-earnings performance
• Positive Sentiment: HC Wainwright initiated coverage with a “Strong Buy” rating, providing a new bullish analyst view. HC Wainwright stock recommendations
• Neutral Sentiment: HC Wainwright’s forecasts show losses continuing in coming years, though its estimates narrow to a $0.14-per-share loss by 2030. The longer-term outlook is therefore still dependent on commercial growth and pipeline progress.
• Neutral Sentiment: A separate report put Denali’s valuation back in focus after the earnings-driven move, suggesting investors may weigh the improved results against the stock’s valuation. Denali earnings and valuation article

Denali Therapeutics Company Profile

Denali Therapeutics is a biotechnology company focused on developing medicines for neurodegenerative diseases and other disorders involving the nervous system. Founded in 2015, the company is headquartered in South San Francisco, California.

Its research and development programs target conditions including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and lysosomal storage disorders. Denali's portfolio includes investigational drug candidates that aim to address underlying disease processes, as well as its TransportVehicle platform, designed to help therapeutic molecules cross the blood-brain barrier.

Denali was co-founded by Ryan Watts, who serves as the company's chief executive officer.

Want to see what other hedge funds are holding DNLI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.